Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1309-1315

  Mukaide, Hiromi ^a   Adachi, Yasushi ^a   Koike Kiriyama, Naoko ^a   Suzuki, Yasuhiro ^a   Minamino, Keizo ^a   Iwasaki, Masayoshi ^a   Tsuda, Masanobu ^a   Nakano, Keiji ^a   Koike, Yasushi ^a   Shigematsu, Akio ^a   Kamiyama, Yasuo ^a   Ikehara, Susumu ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti tumor therapy; Dendritic cells; Donor lymphocyte infusion; Graft versushost disease; Intra bone marrow bone marrow transplantation

Indexed keywords

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MOUSE; TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DENDRITIC CELLS; GRAFT VS HOST DISEASE; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; MICE; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34447266441     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1309     Document Type: Article

References (52)

1. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758, 2000.
2. Zetterquist H, Hentschke P, Thorne A, et al: A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 28: 1161-1166, 2001. (Pubitemid 34082975)
3. + cell dose, GVHD and disease response. Bone Marrow Transplant 34: 511-514, 2004.
4. Eibl B, Schwaighofer H, Nachbaur D, et al: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88: 1501-1508, 1996.
5. Slavin S, Morecki S, Weiss L and Or R: Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 11: 265-276, 2002. (Pubitemid 34309520)
6. Tsukada N, Kobata T, Aizawa Y, Yagita H and Okumura K: Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93: 2738-2747, 1999.
7. Hattori K, Hirano T, Miyajima H, et al: A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Br J Haematol 105: 303-312, 1999.
8. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100, 2002.
9. Yung I, Weiss L, Abdul-Hai A, Kasir J, Reich S and Slavin S: Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. Cancer Res 65: 9735-9740, 2005. (Pubitemid 41541450)
10. Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM and Fuchs EJ: Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 101: 1645-1652, 2003.
11. Slavin S, Ackerstein A, Morecki S, Gelfand Y and Cividalli G: Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant 28: 795-798, 2001.
12. - donor lymphocyte infusion. Stem Cells 23: 365-370, 2005.
13. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
14. Tsujitani S, Furukawa Y, Tamada R, Okumura T, Yasumoto K and Sugimachi K: Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 59: 501-505, 1987. (Pubitemid 17002430)
15. Schronder S, Schwarz W, Rehpenning W, Loning T and Bocker W: Dendritic/langerhans cells and prognosis in patients with papillary thyroid carcinomas, immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am J Clin Pathol 89: 295-300, 1988.
16. Furihata M, Ohtsuki Y, Ido E, et al: HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma - their distribution in relation to prognosis. Virchows Arch B Cell Pathol Incol Mol Pathol 61: 409-414, 1992.
17. Gong J, Chen D, Kashiwaba M and Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3: 558-561, 1997. (Pubitemid 27198656)
18. + cytotoxic T lymphocytes. Int J Cancer 87: 553-558, 2000.
19. Tsunoda T, Tanimura H, Yamaue H, Tanaka H and Matsuda K: Tumor specific CTL therapy for advanced cancer and development for cancer vaccine. Hepatogastroenterology 46: 1287-1292, 1999.
20. Tjoa BA, Elgamal AA and Murphy GP: Vaccine therapy for prostate cancer. Urol Clin North Am 26: 365-374, 1999.
21. Tuting T, Wilson CC, Martin DM, et al: Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 160: 1139-1147, 1998.
22. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36: 129-138, 1998.
23. Sato M, Iwakabe K, Kimura S and Nishimura T: Functional skewing of bone marrow-derived dendritic cells by Th1- or Th2-inducing cytokines. Immunol Lett 67: 63-68, 1999.
24. Sato M, Iwakabe K, Ohta A, et al: Functional heterogeneity among bone marrow-derived dendritic cells conditioned by Th1- and Th2- biasing cytokines for the generation of allogeneic cytotoxic T lymphocytes. Int Immunol 12: 335-342, 2000.
25. Nishimura T, Iwakabe K, Sekimoto M, et al: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190: 617-627, 1999.
26. Kushida T, Inaba M, Hisha H, et al: Intra-bone marrow injection of allogenic bone marrows: a powerful new strategy for treatment of intractable autoimmune diseases in MLR/lpr mice. Blood 97: 3292-3299, 2001.
27. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM and Ferrara JLM: An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. the roles of minor H antigens and endotoxin. Blood 8: 3230-3239, 1996. (Pubitemid 26357409)
28. Koike Y, Adachi Y, Suzuki Y, et al: Allogeneic intra-bone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats. Stem Cells (In press).
29. Barge RM, Osanto S, Marijt WA, et al: Minimal GVHD following in vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumor. Exp Hematol 31: 865-872, 2003.
30. Papadopoulos EB, Ladanyi M, Emanuel D, et al: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330: 1185-1191, 1994.
31. Kishi Y, Kami M, Oki Y, et al: Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow Transplant 26: 573-576, 2000.
32. Hromas R, Cornetta K, Srour E, Blanke C and Broun ER: Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 84: 1689-1690, 1994. (Pubitemid 24273046)
33. Yoshihara S, Kato R, Inoue T, et al: Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. Transplantation 77: 835-838, 2004.
34. Bregni M, Dodero A, Peccatori J, et al: Non-myeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99: 4234-4236, 2002.
35. Childs RW, Clave E, Tisdale J, Plante M, Hensel N and Barrett J: Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 17: 2044-2049, 1999. (Pubitemid 29318833)
36. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL: Two types of murine helper T cell clone. I, Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986. (Pubitemid 16136806)
37. Chen Y, Kuchroo VK, Inobe J, Hafler DA and Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237-1240, 1994. (Pubitemid 24291983)
38. Mosmann TR and Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996.
39. Paul WE and Seder RA: Lymphocyte responses and cytokines. Cell 76: 241-251, 1994.
40. Nakamura K, Inaba M, Sugiura K, et al: Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion. Stem Cells 22: 125-134, 2004. (Pubitemid 38282628)
41. Blanc KL, Rasmusson I, Sundberg B, et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441, 2004. (Pubitemid 38586721)
42. Kuroiwa T, Kakishita E, Hamano T, et al: Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest 107: 1365-1373, 2001. (Pubitemid 32522030)
43. Nicola MD, Carlo-Stella C, Magni M, et al: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843, 2002.
44. Beyth S, Borovsky Z, Mevorach D, et al: Human mesenchymal stem cells after antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214-2219, 2005. (Pubitemid 40731815)
45. Aggarwal S and Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822, 2005.
46. Imado T, Iwasaki T, Kataoka Y, Kuroiwa T, Hara H, Fujimoto J and Sano H: Hepatocyte growth factor preserves graft-versusleukemia effect and T-cell reconstitution after marrow transplantation. Blood 104: 1542-1549, 2004.
47. Blaser BW, Roychowdhury S, Kim DJ, et al: Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 105: 894-901, 2005.
48. Alpdogen O, Eng JM, Muriglan JS, et al: Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105: 865-873, 2005.
49. Sykes M, Sharabi Y and Sachs DH: Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant 3: 379-386, 1988.
50. Khouri IF, Saliba RM, Giralt SA, et al: Non-ablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus- host disease, and treatment-related mortality. Blood 98: 3592-3599, 2001.
51. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH- 1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood 96: 2419-2425, 2000.
52. Mattsson J, Uzunel M, Brune M, et al: Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 115: 935-944, 2001.